Minneapolis-based Metavention designed its integrated radiofrequency (iRF) renal denervation system to treat hypertension. The company plans for its randomized, double-blinded, sham-controlled RADAR study to enroll up to 300 patients across 50 centers. This pivotal study evaluates the safety and efficacy of the iRF renal denervation system.
Metavention designed its iRF denervation system to provide an important distinction to renal denervation procedures: it requires only a single ablation cycle per kidney. The company believes this approach could simplify procedures and reduce the overall burden on patients undergoing renal denervation.
The catheter-based, minimally invasive procedure uses an integrated, multi-RF electrode balloon. It als…